Quantifying the impact of a novel virus on the economic value of pathogen reduction technology for platelets
At current prices, PRT is unlikely to be cost-effective when judged against thresholds for medicines and treatments. Given significant additional willingness-to-pay for blood safety, PRT is only likely to be cost-effective if a novel virus that causes chronic infection with significant morbidity and mortality emerges very soon after the introduction of PRT.
Authors
- Adam Irving (ORCID: https://orcid.org/0000-0002-0406-658X)
- Stephen Thomas (ORCID: https://orcid.org/0000-0001-7761-7138)
- Peter Simmonds (ORCID: https://orcid.org/0000-0002-7964-4700)
- William L. Irving (ORCID: https://orcid.org/0000-0002-7268-3168)
- James Neuberger
Institutions
- NHS Blood and Transplant (GB)
- Nottingham University Hospitals NHS Trust (GB)
- University of Nottingham (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- University of Oxford (GB)
- Nottingham Biomedical Research Centre (GB)
- Monash University (AU)
Publication Details
- Journal
- Transfusion
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1111/trf.18115
- Citations
- 1
- Primary Topic
- Parvovirus B19 Infection Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39